Sofinnova Partners’ Post

🌐 Bryan, Garnier & Co acts as Joint Bookrunner to Swedish biopharmaceutical company Camurus on a Follow-on Offering of SEK 1,090m. Discover more here: https://lnkd.in/gSkjQZ6J 🔬 With its strong R&D expertise and proprietary FluidCrystal® technology, Camurus develops innovative, long-acting treatments for extended efficacy with a single injection. 🤝 Bryan Garnier remains committed to backing growth companies striving to develop and commercialize innovative and differentiated treatments. This marks the third fundraise for Nordic BioPharma over the past few months including Calliditas Therapeutics EUR 92m Debt Financing and Egetis Therapeutics AB's SEK 462m Combined Equity and Debt Offering, demonstrating once again our unique ability to raise capital for European healthcare companies in a highly competitive fundraising environment. 💰 Other recent deals with pioneers striving for a healthier future include Abivax’s structured debt financing transactions for up to EUR 150m followed by the company’s USD 236m Nasdaq IPO, Median Technologies’ EUR 21.6m Follow-on Offering & Convertible Bonds Issuance, and MedinCell’s EUR 25m Follow-on Offering. #Biotech #Biopharma #Chronic #Longacting #Camurus #BryanGarnier Pierre Kiecolt-Wahl, Vincent Meunier, Paul Lequeux, Gustaf Orsucci, Theodore de Charsonville, Pierre-Etienne Bénaich

In the lead up to its capital markets day, Basilea Pharmaceutica announced it has received initial funding of up to US$0.9m through a grant from Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), a global non-profit partnership backed by governments and foundations, for its preclinical antibiotics program. CARB-X is focused on supporting early-stage antibacterial research and development, and this grant is expected to support development work up until clinical candidate nomination in H224, with potential additional funding subject to achieving certain milestones. 2024 is shaping up to be an active year for Basilea, following the recent FDA approval and anticipated subsequent commercial launch of Zevtera in the US, as well as the initiation of Phase III studies for newly acquired antifungal asset Fosmanogepix (mid-2024).  Edison Group #pharmaceutical #treatment #zevtera https://lnkd.in/dnwWZ3bh  

The Column Group (TCG) unveils its innovative strategy for funding single-asset biologic companies with the launch of TCG Labs and Soleil, a Bay Area R&D hub. With over $400 million raised for this initiative, TCG aims to streamline drug development and address challenges in the biotech industry, such as escalating research costs and talent retention. Led by CEO Jin-Long Chen, Soleil will focus on early-stage research and Phase I or II trials before offering single assets to larger biotech or pharmaceutical firms. This approach aims to maximize returns for founders and investors while maintaining a core team of researchers at Soleil. TCG's model diverges from traditional biotech startup strategies, emphasizing asset sales over company acquisitions. By concentrating solely on single assets, TCG Labs seeks to provide a more efficient and sustainable path to drug development. With experienced leadership, including Lucinda Quan and NGM veterans, TCG Labs sets ambitious goals in disease areas like oncology, autoimmune, and cardiovascular diseases. The firm's track record of successful exits through M&A underscores its commitment to generating value for investors and fostering long-term research initiatives. As TCG Labs-Soleil emerges as a pioneering force in biotech funding, its innovative approach promises to reshape the landscape of drug development and investment strategies in the biopharmaceutical industry. Source: https://lnkd.in/eC4m9eRN

🌟 Unlocking Q1 2024's Biopharma Boom: Key Insights from DealForma’s Latest Venture Funding Report: - Total Investment: A robust $6.5 billion over 104 funding rounds, showing a shift towards larger investments per round compared to Q4 2023's $4.9 billion across 111 deals. - Leading Deals: - Alumis spearheaded the quarter with $259M for next-gen immune therapies. - Sionna Therapeutics followed closely with $182M aimed at pioneering cystic fibrosis treatments. - Capstan Therapeutics secured a $175M Series B for their innovative CAR-T candidate, CPTX2309, aimed at treating autoimmune disorders. - BioAge Labs raised $170M in Series D funding to advance a groundbreaking experimental pill targeting weight loss, potentially rivaling medications like #Wegovy and #Zepbound. - Bayer | Pharmaceuticals and RTW Investments, LP invested €148M ($159M USD) in Jixing Pharmaceuticals to support its innovative treatments in cardiovascular disease and ophthalmology in China. - Top Therapeutic Areas: Cancer and neurological disorders were the focal points, attracting substantial investments reflecting the urgent demand for breakthroughs in these fields. - Sector Trends & Innovation in Technologies: The funding landscape favored small molecule and biologic platforms - Geographical Insights: North America continues to lead in funding allocations, demonstrating its central role in global biopharma innovation. For a comprehensive analysis, including investment trends, technology focus, and strategic insights, explore the full report [here](https://lnkd.in/eKbqpMCi). 📈 #Biopharma #VentureCapital #Innovation #Biotech #bioCatalyst

Thoughts on this? >> Sofinnova’s Jim Healy on ‘more rational market’ as four biotech startups near their IPOs >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #healthcare #pharmaceutical #pharma #productmarketing

Thoughts on this? >> Merck pens pact with Pearl Bio for new biologics in cancer >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #productmarketing #biotech #healthcare

China’s funding continues to peter out in 2023. Based on data gathered by PharmaDJ, Chinese biopharmaceutical companies raised a disclosed total of $4.8 billion from 203 deals, a 41% drop from $8.1 billion in 2022. 10m deals remained undisclosed. Yet, despite a wider market slump, nine drugmakers raised funds at least $100 million. Treatments for cancer, autoimmune and metabolic diseases enjoyed considerably more investor attention in 2023. Nine Chinese drug developers completed their initial public offerings in 2023. 2023 saw 145 licensing transactions in China. 30 were in-licensing deals for new assets from overseas, sharply down compared to 59 in 2022 and 105 in 2021. Compared to 2022, in-licensing deal values decreased from $19.5 billion to $2.6 billion. Chinese companies inked 73 out-licensing transactions, considerably higher than 2022’s 33. Compared to 2022, out-licensing deals grew from $11.6 billion to $42.5 billion. https://lnkd.in/gg3n3iMM

Thoughts on this? >> Elion Therapeutics raises $81M Series B for antifungal treatment >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #healthcare #productmarketing #biotech

Thoughts on this? >> Elion Therapeutics raises $81M Series B for antifungal treatment >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #productmarketing #pharma #healthcare #pharmaceutical #biotech

Company Spotlight: Apollo Therapeutics 📣 Founded:  Founded in 2016 by Dr. Richard Mason (CEO). 📣 Specialized In:  Apollo Therapeutics is a portfolio biopharmaceutical company that focuses on translating cutting-edge medical research into innovative medicines. Utilizing a hub-and-spoke operational model, Apollo collaborates with leading academic institutions to discover and develop new therapeutic programs. The company has built a broad and diversified pipeline consisting of over 20 programs targeting major commercial markets and is committed to addressing unmet medical needs through high-quality science. 📣 Funding:  Apollo recently closed a $226.5 million financing round, significantly augmenting the $195 million previously raised. This funding will be instrumental in advancing its clinical programs and supporting ongoing drug discovery efforts. Key Investors:  ➡ Patient Square Capital (lead investor)  ➡ M&G plc  ➡ Rock Springs Capital #BiopharmaInnovation #HealthcareInvestment #DrugDevelopment #Pharma #InnovativeTherapies